Company intelligence / Profile preview

Axoft

Cambridge, Massachusetts, United Statesaxoft.us ↗

Ownership: Private
Employees: ~25
Development stage: Preclinical

Overview

Axoft has successfully completed the first four cases of its first-in-human clinical study ("FINESSE") with its ultrasoft, high-density iBCI made from Fleuron™ material. The device demonstrated safety and functionality in human patients undergoing brain tumor resection, reliably recording high-density single-neuron activity across cortical and subcortical regions. The implant showed minimal disruption to tissue and superior data quality compared to existing rigid electrodes.

Therapeutic areas: Neurology
Modalities: DeviceImplantable electronicsBrain-computer interface (iBCI)
Industry: Implantable Medical Devices

Partnerships

Harvard University (licensing agreement for core technology)

Beyond the preview

Go deeper on Axoft.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Axoft.

Explore the full profile